Radiotherapy and Radiosurgery Department, Humanitas Research Hospital and Cancer Center, Milan-Rozzano, Italy.
Radiotherapy and Radiosurgery Department, Humanitas Research Hospital and Cancer Center, Milan-Rozzano, Italy.
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):785-793. doi: 10.1016/j.ijrobp.2017.10.040. Epub 2017 Oct 31.
To evaluate the excess absolute risk (EAR) comparing volumetric modulated arc therapy (VMAT) and 3-dimensional (3D) conformal radiation therapy (CRT) in breast cancer radiation therapy treatment.
Two VMAT arrangements (VMAT_tang and VMAT_full, i.e. partial arcs with and without a sector of 0 Monitor Unit, respectively) and a 3D CRT (field-in-field [FinF]) plan were calculated with an accurate dose calculation algorithm, Acuros, in 20 patients presenting with early-stage breast cancer. The dose prescription was 40.05 Gy in 15 fractions. The planning aim was to maximize the dose reduction in the lungs, contralateral breast, heart, and coronary artery. EAR was estimated using different models: linear, linear-exponential, plateau, and full model, which better uses a carcinogenesis model and epidemiologic data for carcinoma induction and which accounts for cell repopulation or repair during the radiation therapy dose fractionation. EAR was computed for contralateral structures-breast and lung-as well as the ipsilateral lung. Normal tissue complication probability (NTCP) was computed to estimate the ipsilateral lung, heart, and skin toxicity, to balance with respect to second cancer induction.
The planning objectives were fulfilled with all the planning techniques. EAR for contralateral breast carcinoma induction, estimated with the most accurate model, was 1.7, 2.4, and 8.5 (per 10,000 patients per year) with FinF, VMAT_tang, and VMAT_full, respectively. For the contralateral lung, these figures were 1.5, 1.6, and 7.3 (per 10,000 patients per year), respectively. NTCP for all the analyzed endpoints was significantly higher with FinF relative to both VMAT settings, with VMAT_full presenting the lowest toxicity risk.
VMAT, in particular with the VMAT_tang setting, could have the same risk of second cancer induction as 3D CRT delivered with the FinF setting for the contralateral organs while reducing acute and late NTCP for the ipsilateral organs. VMAT might be considered a safe technique for breast cancer treatment for those aspects.
评估容积旋转调强放疗(VMAT)和三维适形放疗(3D-CRT)在乳腺癌放疗治疗中的超额绝对风险(EAR)。
在 20 例早期乳腺癌患者中,使用精确剂量计算算法 Acuros 计算了两种 VMAT 布置(VMAT_tang 和 VMAT_full,即分别带有和不带有 0 监测单位扇形的部分弧)和一种 3D-CRT(场中场[FinF])计划。处方剂量为 40.05Gy,共 15 个分次。计划目标是最大限度地减少肺部、对侧乳房、心脏和冠状动脉的剂量。使用不同的模型(线性、线性-指数、平台和全模型)来估计 EAR,这些模型更好地利用了致癌模型和流行病学数据来诱导癌,并考虑了在放疗剂量分割过程中的细胞再增殖或修复。计算了对侧结构-乳房和肺-以及同侧肺的 EAR。计算了正常组织并发症概率(NTCP),以估计同侧肺、心脏和皮肤毒性,以平衡继发癌症的诱导。
所有的计划技术都达到了计划目标。使用最准确的模型估计对侧乳腺癌诱导的 EAR,FinF、VMAT_tang 和 VMAT_full 分别为 1.7、2.4 和 8.5(每 10000 例患者每年)。对于对侧肺,这些数字分别为 1.5、1.6 和 7.3(每 10000 例患者每年)。对于所有分析的终点,FinF 与两种 VMAT 方案相比,NTCP 显著更高,VMAT_full 表现出最低的毒性风险。
VMAT,特别是 VMAT_tang 方案,在降低同侧器官的急性和晚期 NTCP 的同时,可能与 FinF 相比,对双侧器官的继发癌症诱导风险相同。从这些方面来看,VMAT 可以被认为是治疗乳腺癌的一种安全技术。